The type IV phosphodiesterase inhibitor rolipram disturbs expression and extinction of conditioned fear in mice

Neuropharmacology

Volumn 59, Issue 1-2, 2010, Pages 1-8

  Mueller, Erik M ^a   Hofmann, Stefan G ^b   Cherry, James A ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Anxiety; camp; Fear potentiated startle; Memory; Response inhibition

Indexed keywords

CYCLIC AMP; ROLIPRAM; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL MOUSE; FEAR; FEAR POTENTIATED STARTLE; LONG TERM MEMORY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; ANIMAL; CONDITIONED REFLEX; DOSE RESPONSE; DRUG EFFECTS; LEARNING; NEUROPSYCHOLOGICAL TEST; RANDOMIZATION; REINFORCEMENT; STARTLE REFLEX;

ANIMALS; CONDITIONING, CLASSICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTINCTION, PSYCHOLOGICAL; FEAR; LEARNING; MALE; MICE; NEUROPSYCHOLOGICAL TESTS; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHODIESTERASE INHIBITORS; RANDOM ALLOCATION; REFLEX, STARTLE; ROLIPRAM;

EID: 77953275284     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.03.002     Document Type: Article

References (48)

1. Alberini C.M. Genes to remember. J. Exp. Biol. 1999, 202:2887-2891.
2. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15020-15025.
3. Barad M. Later developments: molecular keys to age-related memory impairment. Alzheimer Dis. Assoc. Disord. 2003, 17:168-176.
4. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 1997, 21:783-789.
5. Bourtchouladze R., Lidge R., Catapano R., Stanley J., Gossweiler S., Romashko D., Scott R., Tully T. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10518-10522.
6. Bouton M.E. Context and behavioral processes in extinction. Learn. Mem. 2004, 11:485-494.
7. Carlezon W.A., Duman R.S., Nestler E.J. The many faces of CREB. Trends Neurosci. 2005, 28:436-445.
8. Cherry J.A., Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 1999, 407:287-301.
9. Comery T.A., Martone R.L., Aschmies S., Atchison K.P., Diamantidis G., Gong X., Zhou H., Kreft A.F., Pangalos M.N., Sonnenberg-Reines J., Jacobsen J.S., Marquis K.L. Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:8898-8902.
10. Davis R.L., Cherry J., Dauwalder B., Han P.-L., Skoulakis E. The cyclic AMP system and Drosophila learning. Mol. Cell. Biochem. 1995, 150:271-278.
11. Davis M. Neural systems involved in fear and anxiety measured with fear-potentiated startle. Am. Psychol. 2006, 61:741-756.
12. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 2004, 114:1624-1634.
13. Gray J.A., McNaughton N. The Neuropsychology of Anxiety: An Enquiry into the Functions of the Septohippocampal System 2000, Oxford University Press, Oxford, UK. second ed.
14. Hofmann S.G. Enhancing exposure-based therapy from a translational research perspective. Behav. Res. Ther. 2007, 45:1987-2001.
15. Isiegas C., Park A., Kandel E.R., Abel T., Lattal K.M. Transgenic inhibition of neuronal protein kinase A activity facilitates fear extinction. J. Neurosci. 2006, 26:12700-12707.
16. Josselyn S.A., Shi C., Carlezon W.A., Neve R.L., Nestler E.J., Davis M. Long-term memory is facilitated by cAMP response element-binding protein overexpression in the amygdala. J. Neurosci. 2001, 21:2404-2412.
17. Kanes S.J., Tokarczyk J., Siegel S.J., Bilker W., Abel T., Kelly M.P. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007, 144:239-246.
18. Kehne J.H., Boulis N.M., Davis M. Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats. Psychopharmacology (Berl.) 1991, 105:27-36.
19. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
20. Kim J.H., Richardson R. The effect of temporary amygdala inactivation on extinction and re-extinction of fear in the developing rat: unlearning as a potential mechanism for extinction early in development. J. Neurosci. 2008, 28:1282-1290.
21. Krupa D.J., Thompson R.F. Inhibiting the expression of a classically conditioned behavior prevents its extinction. J. Neurosci. 2003, 23:10577-10584.
22. Langton J.M., Richardson R. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 2008, 33:3096-3102.
23. Laurent V., Marchand A.R., Westbrook R.F. The basolateral amygdala is necessary for learning but not for relearning extinction of context conditioned fear. Learn. Mem. 2008, 15:304-314.
24. LeDoux J. The amygdala. Curr. Biol. 2007, 17:R868-R874.
25. Li Y.F., Huang Y., Amsdell S.L., Xiao L., O'Donnell J.M., Zhang H.T. Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor Rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus. Neuropsychopharmacology 2009, 34:2404-2419.
26. Meloni E.G., Jackson A., Gerety L.P., Cohen B.M., Carlezon W.A. Role of the bed nucleus of the stria terminalis (BST) in the expression of conditioned fear. Ann. N.Y. Acad. Sci. 2006, 1071:538-541.
27. Monti B., Berteotti C., Contestabile A. Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2006, 31:278-286.
28. Morgan M.A., Romanski L.M., LeDoux J.E. Extinction of emotional learning: contribution of medial prefrontal cortex. Neurosci. Lett. 1993, 163:109-113.
29. Myers K.M., Davis M. Mechanisms of fear extinction. Mol. Psychiatry 2007, 12:120-150.
30. Myers K.M., Ressler K.J., Davis M. Different mechanisms of fear extinction dependent on length of time since fear acquisition. Learn. Mem. 2006, 13:216-223.
31. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J. Neurosci. 1996, 16:2365-2372.
32. Overton D.A. Historical context of state dependent learning and discriminative drug effects. Behav. Pharmacol. 1991, 2:253-264.
33. Pandey S.C., Zhang H., Roy A., Xu T. Deficits in amygdaloid cAMP-responsive element-binding protein signaling play a role in genetic predisposition to anxiety and alcoholism. J. Clin. Invest. 2005, 115:2762-2773.
34. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 2000, 20:349-374.
35. Quirk G.J., Mueller D. Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 2008, 33:56-72.
36. Ramos B.P., Birnbaum S.G., Lindenmayer I., Newton S.S., Duman R.S., Arnsten A.F. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 2003, 40:835-845.
37. Randt C.T., Judge M.E., Bonnet K.A., Quartermain D. Brain cyclic AMP and memory in mice. Pharmacol. Biochem. Behav. 1982, 17:677-680.
38. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl.) 2009, 202:419-443.
39. Rescorla R.A. Response-inhibition in extinction. Q. J. Exp. Psychol. B 1997, 50B:238-252.
40. Rutten K., Prickaerts J., Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem. 2006, 85:132-138.
41. Silvestre J.S., Fernandez A.G., Palacios J.M. Effects of rolipram on the elevated plus-maze test in rats: a preliminary study. J. Psychopharmacol. 1999, 13:274-277.
42. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983, 22:267-272.
43. Waddell J., Dunnett C., Falls W.A. C57BL/6J and DBA/2J mice differ in extinction and renewal of extinguished conditioned fear. Behav. Brain Res. 2004, 154:567-576.
44. Wang H., Ferguson G.D., Pineda V.V., Cundiff P.E., Storm D.R. Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP. Nat. Neurosci. 2004, 7:635-642.
45. Zeller E., Stief H.J., Pflug B., Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry. 1984, 17:188-190.
46. Zhang H.T., Crissman A.M., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000, 23:198-204.
47. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 2002, 27:587-595.
48. Zhang H.T., Zhao Y., Huang Y., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 2004, 1432-1439.